Literature DB >> 15950904

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.

Yili Yang1, Robert L Ludwig, Jane P Jensen, Shervon A Pierre, Maxine V Medaglia, Ilia V Davydov, Yassamin J Safiran, Pankaj Oberoi, John H Kenten, Andrew C Phillips, Allan M Weissman, Karen H Vousden.   

Abstract

The p53 tumor suppressor protein is regulated by its interaction with HDM2, which serves as a ubiquitin ligase (E3) to target p53 for degradation. We have identified a family of small molecules (HLI98) that inhibits HDM2's E3 activity. These compounds show some specificity for HDM2 in vitro, although at higher concentrations effects on unrelated RING and HECT domain E3s are detectable, which could be due, at least in part, to effects on E2-ubiquitin thiol-ester levels. In cells, the compounds allow the stabilization of p53 and HDM2 and activation of p53-dependent transcription and apoptosis, although other p53-independent toxicity was also observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950904     DOI: 10.1016/j.ccr.2005.04.029

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  125 in total

1.  Ubiquitination: Added complexity in Ras and Rho family GTPase function.

Authors:  Michelle de la Vega; James F Burrows; James A Johnston
Journal:  Small GTPases       Date:  2011-07-01

2.  Tumor suppression and normal aging in mice with constitutively high p53 activity.

Authors:  Susan M Mendrysa; Kathleen A O'Leary; Matthew K McElwee; Jennifer Michalowski; Robert N Eisenman; Douglas A Powell; Mary Ellen Perry
Journal:  Genes Dev       Date:  2006-01-01       Impact factor: 11.361

Review 3.  Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc.

Authors:  Mu-Shui Dai; Yetao Jin; Jayme R Gallegos; Hua Lu
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

4.  Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Sheng Zhou; Yuhong Du; Jing Xiong; Sha Yi; Cheng-Kui Qu; Haian Fu; Muxiang Zhou
Journal:  Cancer Cell       Date:  2016-09-22       Impact factor: 31.743

Review 5.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 6.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 7.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 8.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 9.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

Review 10.  Chemical Biology Framework to Illuminate Proteostasis.

Authors:  Rebecca M Sebastian; Matthew D Shoulders
Journal:  Annu Rev Biochem       Date:  2020-02-25       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.